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Background: Questionnaires are often used in assessing health-related quality of life in
patients with chronic obstructive pulmonary disease (COPD). It is important that these ques-
tionnaires have good reliability, validity, and responsiveness. The aim of this study was to
investigate and compare these properties in the disease specific Clinical COPD Questionnaire
(CCQ) and the Chronic Respiratory Questionnaire self-reported (CRQ-SR).
Methods: Two hundred ninety six participants with spirometry confirmed mild to moderate
COPD were included in a smoking cessation trial. It was assumed that health-related quality
of life would improve in participants who stopped smoking. The questionnaires were adminis-
tered at baseline and at weeks 5, 26, and 52 after the target quit date.
Results: At baseline, 292 (97%) participants returned the CCQ and 296 (100%) the CRQ-SR ques-
tionnaire. For both instruments, the internal consistency was good (Cronbach’s alpha >70%) as
was the convergent validity with each other but not with spirometry. The CCQ was responsive
to improvements in respiratory symptoms at both week 26 (1.02, SDZ 0.81) and 52 (1.04,
SD Z 0.91) and in the total score at week 26 (0.54, SD Z 0.50) and 52 (0.43, SD Z 0.44).ive pulmonary disease; HRQoL, health-related quality of life; CCQ, clinical COPD questionnaire; CRQ,
-SR, CRQ self reported; CRQ-IL, CRQ interviewer led; GOLD, global initiative for chronic obstructive
ilator; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; MCID, minimal clinically
3882893; fax: þ31 43 3619344.
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1676 A.A. Reda et al.The mastery domain and the total score of the CRQ-SR were responsive at week 26 (1.14,
SD Z 0.82; 0.67, SD Z 0.97 respectively) but not at week 52 (0.04, SD Z 0.93; 0.38,
SD Z 0.57 respectively).
Conclusion: Both the CCQ and CRQ-SR are equally reliable and valid. The long-term responsive-
ness of the CCQ is better. Both questionnaires can be used in future studies involving patients
with mild to moderate COPD. However, when the follow-up exceeds 26 weeks, the CCQ is the
recommended alternative.
Netherlands Trial Register: ISRCTN 64481813.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Generic health-related quality of life (HRQoL) question-
naires measure general health status, while disease specific
HRQoL questionnaires are concerned with specific diseases,
such as chronic obstructive pulmonary disease (COPD). The
Clinical COPD Questionnaire (CCQ)1 and Chronic Respiratory
Questionnaire (CRQ)2 are disease specific HRQoL question-
naires for measuring respiratory health status.
The CCQ has three domains: symptoms, functional state,
and mental state.1 It has good validity, reliability and
responsiveness in patients at risk of COPD and patients with
COPD.1,3 The CRQ is composed of four domains: fatigue,
dyspnoea, mastery (the patient’s feeling of control over
their disease), and emotional function.2,4 It has good
convergent validity with most of the commonly used
generic and disease specific HRQoL questionnaires.4e7
HRQoL and functional status are important aspects of
COPD care. The CCQ and CRQ have shown to be adequate
instruments in moderate to severe COPD1,5,8 but evidence is
limited in mild to moderate COPD, especially in the long-
term follow-up. Yet, the majority of patients with COPD
have mild to moderate symptoms and evidence on validity
and reliability of CCQ and CRQ is necessary to improve the
applicability of these instruments in this group of patients.
Furthermore, the question remains which of the two
questionnaires performs best in these patients. To date,
there are no comparison studies between the CCQ and CRQ.
In order to compare and assess the adequacy of these
instruments one needs longitudinal data in which the
functional status and HRQoL are expected to change clearly
within patients with mild to moderate COPD. So we need
a situation, such as the improvement in HRQoL and respi-
ratory symptoms which follows quitting smoking,9,10 in
which CCQ and CRQ are measured in a standardized way.
The aim of this study was to assess and compare the
medium- and longer-term reliability, validity, and respon-
siveness of the CCQ and the CRQ in a smoking cessation trial
in smokers with mild to moderate airflow limitation.
Methods
The data for this study came from a recently completed
randomized controlled trial11 which aimed to test the effi-
cacy of smoking cessation interventions in smokers withmild
to moderate airflow limitation. Prolonged abstinence rate
for thewhole samplewas 23% atweek 26 and 10% atweek 52.
The results of the efficacy of the smoking cessation inter-
vention from this trial have been discussed elsewhere.12A total of 296 participants were included, all with mild
(defined as Global Initiative for Chronic Obstructive Lung
Disease13 (GOLD) I) to moderate (GOLD II) airflow limita-
tion, confirmed by spirometry post bronchodilator (post-
bd.) forced expiratory volume in 1 s (FEV1)/forced vital
capacity (FVC) of <0.70 in combination with post-bd.
FEV1  50% of predicted. For the discriminative validity
analysis we included an external sample of 587 smokers
with normal lung function who were screened for partici-
pation but were found not eligible for the trial. Prolonged
abstinence from smoking was defined as self-reported non-
smoking at week 5, 26, and 52 after the target quit date,
validated by a urine cotinine test (<50 ng/ml).11 The study
was approved by the ethical review committee of Maas-
tricht University Medical Centre and registered at the
Netherlands Trial Register (ISRCTN 64481813).
Clinical COPD questionnaire (CCQ)
The CCQ has three domains: symptoms (4 items), functional
state (4 items) and mental state (2 items), graded on a 7-
point Likert scale from 0 to 6. Lower scores indicate better
health status. Analyses were conducted for participants
with at least 50% completion rate based on the recom-
mendation of the questionnaire designers.
Chronic respiratory questionnaire self-reported
(CRQ-SR)
The underlying structures, content and scoring of the
interviewer lead CRQ (CRQ-IL) and the self-reported CRQ
(CRQ-SR) are the same.4,8,14 In the dyspnoea domain (5
items), patients select from a list of activities which make
them breathless, and they may also add additional activi-
ties.4 The other three domains are standardized: fatigue (4
items), mastery (4 items), and emotional function (7
items). This provides a 7-point Likert score that enables
comparison among the four domains. Lower scores indicate
a greater degree of dysfunction. Data of smokers who
responded to respectively 2, 2, and 4 or more items of the
fatigue, mastery, and emotional function domain were
included in the analyses. This gives at least a 53.3% item-
completion rate for the three domains: all items of the
dyspnoea domain were included in the analysis. All data
analyses were conducted for participants with at least 65%
item-completion rate.
Participants completed the CCQ and CRQ-SR at home
before the baseline measurement (before randomisation)
and at weeks 5, 26, and 52 after the target quit date. Mean
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domain by the corresponding number of items.
Spirometry was conducted at baseline according to the
European Respiratory Society/American Thoracic Society
guidelines.15,16 In this report, we used the post-bd. FEV1/
FVC and FEV1 measurements.
15,16
Data analysis
‘Ceiling effect’ (best health score) and ‘floor effect’
(worst health score) were analysed at baseline. We
assessed both minimal clinically important differences
(MCID) and statistically significant differences. The MCID
for the CCQ and the CRQ-SR were previously estimated to
be 0.417 and 0.5 respectively.18 To correct for multiple
testing, alpha was set at 0.001. SPSS 15 was used for the
analyses.
Sensitivity analyses were conducted in participants with
complete response to all items of the questionnaires that
are included in a given analysis in order to examine the
validity of our findings. We statistically analysed the influ-
ence of background characteristics such as age and sex on
completion rates. We used t-tests or ManneWhitney U tests
for numerical variables and chi-squared test for categorical
variables.
Domain specific consistency assessment was conducted
to examine reliability. A Cronbach’s alpha of more than
0.70 was considered good consistency.19 We compared the
discriminative property of the questionnaires separately
between participants with GOLD I (FEV1/FVC < 0.70,
FEV1  80%) and GOLD II (FEV1/FVC < 0.70,
50%  FEV1 < 80%) COPD; and between participants with
COPD (GOLD I or II) and with normal lung function.
Convergence between the two questionnaires, and the
post-bd. FEV1 measurements was examined using Spear-
man’s rho.
Responsiveness is the ability of an instrument to
measure a clinically meaningful change.19 Theoretical
constructs are commonly employed in validity testing as
there are no gold standard tests. The underlying assump-
tion in our responsiveness analysis was that smoking
cessation improves HRQoL in smokers in the medium- and
long term.10,20,21 We analysed the mean score changes from
baseline for prolonged abstainers at 26 and 52 weeks to test
medium and long-term responsiveness, respectively. The 5-
week scores were not used because quitting smoking may
reduce quality of life in the short term.9,10,22
Results
The mean age of participants was 54 years (SD  7.5).
Baseline characteristics of participants are shown in Table
1.
At baseline, 292 (97%) participants returned the CCQ and
296 (100%) the CRQ-SR questionnaire. Two hundred sixty
eight (92%) and 275 (93%) participants completed all items
of the CCQ and CRQ-SR respectively, while 279 (96%) and
296 (100%) completed at least 50% and 65% of the items on
the CCQ and CRQ-SR respectively. Baseline characteristics
were not statistically associated with item-completion
rates in both questionnaires.One hundred and forty nine (51%) and 146 (49%) partic-
ipants completed all items of the CCQ and CRQ-SR at
baseline and at the follow-up visits in week 5, 26 and 52.
Score distributions
There was no ‘floor’ effect for both questionnaires.
However, there was a modest amount of ‘ceiling’ effect for
some domains (Table 2).
Reliability
The Cronbach’s alpha for the symptoms, functional state,
and mental state of the CCQ was 0.73, 0.77 and 0.59
respectively. This figure was 0.88, 0.91, 0.75, and 0.89 for
the fatigue, dyspnoea, mastery and emotional function
domains of the CRQ-SR.
Discriminant validity
There was a statistically significant difference in age
between the external sample and study participants where
the external sample had a mean age of 48.7 (SD Z 8.1)
years and trial participants 54.0 (SD Z 7.5) (Z 9.02,
p < 0.001). The pack years of smoking for the external
sample was 36.2 (SD Z 19.4) and 43.5 (SD Z 18.9) for trial
participants (Z 6.11, p < 0.001). The domains and total
score of both questionnaires did not discriminate between
participants with COPD (GOLD I and II) and participants with
no airflow limitation. Unlike the domains of the CRQ-SR, the
total score of the CCQ was able to discriminate statistically
between participants with GOLD I and GOLD II COPD (df
277, tZ 3.7, p < 0.001), where the latter group had worse
HRQoL (Table 3).
Convergent validity
There was a statistically significant (p < 0.001) modest
correlation between the baseline scores of the CCQ and
CRQ-SR. FEV1 scores had a very low correlation with both
the CCQ and the CRQ-SR (Table 4).
Responsiveness
Both questionnaires detected a clinically meaningful and
statistically significant improvement in HRQoL in partici-
pants with prolonged abstinence at week 26; this was 1.14
(SD Z 0.82) for the mastery domain of the CRQ-SR and
1.02 (SD Z 0.81) for the symptom domain of the CCQ
(Table 5). In Fig. 1, we standardized (mean/SD) the
responsiveness indicators and scaled improvement in
HRQoL as positive (and worsening negative) to aid between
questionnaire comparisons. As the figure shows, the CCQ
performed better.
The CCQ detected a clinicallymeaningful and statistically
significant improvement in HRQoL in participants with pro-
longed abstinence atweek 52; this was1.04 (SDZ 0.97) for
the symptom domain (Table 5). The CRQ-SR domains and
total score were unable to detect a clinically meaningful and
statistically significant improvement at week 52 except its
dyspnoea domain which indicated a clinically meaningful
Table 1 Baseline characteristics of the study population (N Z 296).a
Sex
Characteristic (Mean, SD) Female (185, 62.5%) Male (111, 37.5%)
Age (years) 54.6 (7.7) 53.0 (7.2)
BMI at baseline (kg/m2)b 25.6 (4.0) 24.1 (4.0)
Number of cigarettes 23.9 (10.0) 22.4 (7.8)
Pack years at baselinec 45.3 (20.1) 40.5 (16.4)
Fagerstro¨m Test for Nicotine Dependenced 4.6 (1.6) 4.4 (1.4)
FEV1 post-bd. %predicted baseline 80.9 (14.2) 82.5 (17.3)
FVC post-bd. %predicted baseline 102.9 (14.8) 110.1 (16.9)
FEV1/FVC post-bd.
e 62.3 (6.2) 63.0 (6.0)
GOLDf COPD classification, N (%)
GOLD I (mild COPD) 103 (64.4%) 57 (35.6%)
GOLD II (moderate COPD) 82 (60.3%) 54 (39.7%)
a Mean (SD) unless indicated otherwise.
b Body Mass Index.
c 1 pack year Z number of cigarettes smoked per day  number of years smoking/20.
d Fagerstro¨m Test for Nicotine Dependence: ranges from 0 (lowest nicotine dependence) to 10 (highest nicotine dependence).
e Post bronchodilator forced expiratory volume in 1 s/forced vital capacity.
f Global Initiative for Chronic Obstructive Lung Disease.
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indicators. Also here, the CCQ performed better.
As a sensitivity analysis, we re-ran all analyses using data
of smokers with 100% item-completion rate to each ques-
tionnaire. There was no difference in the validity and
reliability estimates for both questionnaires.
Discussion
We examined and compared the validity, reliability, and
responsiveness of the Clinical COPD Questionnaire (CCQ)
and the Chronic Respiratory Questionnaire self-reported
(CRQ-SR) in smokers with mild to moderate airflow limita-
tion. Both questionnaires showed good internal consistency
and good convergent validity with each other but not with
spirometry. The CRQ-SR showed good responsiveness for
the mastery domain and total score after 26 weeks follow-
up, and the CCQ showed good responsiveness for theTable 2 Scores of participants at baseline assessment.a
N Mean (SD)
CRQ e SR
Fatigue 296 4.7 (1.2)
Emotional function 296 4.8 (1.1)
Mastery 296 5.2 (1.3)
Dyspnoea 205 3.8 (1.2)
Total 296 4.7(0.9)
CCQ
Symptom 294 2.0 (1.1)
Functional state 286 0.9 (0.8)
Mental state 284 0.9 (1.0)
Total 279 1.2 (0.8)
a The CRQ-SR was rated from 1 ‘worst health condition’ to 7 ‘best he
6 ‘worst health condition’.symptom domain and total score after both medium- (26
weeks) and longer term (52 weeks) follow-up.
We detected no difference in baseline characteristics
between participants with item-completion rates below and
above 50% and 65% of items of CCQ and CRQ, respectively.
This could indicate that the items were approximately
randomly missing with regard to the baseline characteristics
such as age and pack years smoking and hence may not have
biased our analyses significantly. This rate is similar or equal
to previous studies for both questionnaires.1,6
Because of the larger number of items and the longer
time needed for completion of the CRQ-SR, the CCQ seems
to be favoured in terms of feasibility. This has important
implication for both clinical practice and research.
Although the CCQ performed somewhat better, both
questionnaires discriminated poorly between GOLD I and II
COPD. This could be because the questionnaires were not
designed for discriminative purposes. The inclusion of mildMedian ‘Floor’ effects,
% n (worst
health score)
‘Ceiling’ scores,
% n (best
health score)
4.8 0.3 (1) 1.0 (3)
4.7 0.0 (0) 1.7 (5)
5.3 0.0 (0) 12.9 (49)
3.7 0.5 (1) 1 (2)
5.0 0.0(0) 0.0(0)
1.8 0.3 (1) 0.7 (2)
0.8 0.0 (0) 14.7(42)
0.5 0.0 (0) 37.0(105)
1.0 0.0 (0) 0.7(2)
alth condition’. The CCQ is rated from 0 ‘best health condition’ to
Table 3 CCQ and CRQ-SR mean (range) scores at baseline within subgroups.a
Normal lung
function (GOLD 0)
Mild COPD (GOLD I) Moderate COPD (GOLD II)
CRQ-SR
Fatigue 4.6 (1.0e7.0) 4.7 (1.0e7.0) 4.6 (1.2e7.0)
Emotional function 4.7 (1.3e7.0) 4.8 (1.6e7.0) 4.7 (1.7e7.0)
Mastery 5.0 (3.0e7.0) 5.0 (2.7e7.0) 4.9 (1.7e7.0)
Dyspnoea 3.8 (1.0e7.0) 3.7 (1.0e6.0) 3.8 (1.6e7.0)
Total 4.6 (1.9e7.0) 4.7 (2.3e6.8) 4.6 (2.5e6.6)
CCQ
Symptom 1.8 (0.0e5.5) 1.8 (0.0e6.0) 2.2b,c (0.3e5.3)
Functional state 0.9 (0.0e5.5) 0.8 (0.0e5.0) 1.0 (0.0e4.0)
Mental state 0.9 (0.0e6.0) 0.8 (0.0e5.0) 1.0 (0.0e4.0)
Total 1.3 (0.0e4.0) 1.1 (0.0e4.3) 1.5c (0.2e4.7)
a The CCQ is rated from 0 ‘best health state’ to 6 ‘worst health state’ and CRQ-SR from 1 ‘worst health state’ to 7 ‘best health state’.
b significant difference between GOLD 0 and GOLD II participant scores.
c significant difference between GOLD I and GOLD II participant scores.
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the performance of the questionnaires as compared to the
situation in which a diverse case mix is available, especially
with more severe cases of COPD.
The internal consistency of the CCQ was lower than that
of the CRQ-SR which reached 0.90 for the emotional and
fatigue domains. The higher alpha for the CRQ-SR could be
due the higher number of items for the domains such as
emotional function. The internal consistency of the CRQ-SR
in this report is similar to8 or higher6 than earlier reports.
Even though previous findings indicated a low internal
consistency of the dyspnoea domain in the range of
0.53e0.64,6,8 we found a very high figure (0.91). Interest-
ingly, our finding is similar to that Rutten-van Mo¨lken et al.
reported (0.86).7 In general, both questionnaires had good
internal consistency, supporting the assumption that the
respective questionnaire items are related to each other.
The statistically significant albeit modest correlation
between the two questionnaires could indicate that they
may be measuring the same target clinical condition. We
could not compare our findings with that of other investi-
gators since this study was the first to compare the CCQ and
CRQ-SR. There was very poor linear correlation between
the CCQ and CRQ-SR with FEV1 post-bd measurements atTable 4 Correlation between the CCQ, CRQ-SR and FEV1 post-b
CCQ domains
Total Symptom
CRQ-SR domains
Fatigue 0.58* 0.35*
Emotional function 0.61* 0.42*
Mastery 0.56* 0.43*
Dyspnoea 0.42* 0.35*
Total 0.72* 0.50*
FEV1post-bd baseline
b 0.19 0.20
*p < 0.001.
a Spearman’s rank correlation (r).
b forced expiratory volume in 1 s.baseline. This finding is similar to other studies on the CRQ-
SR7 and CRQ -IL8 but not for the CCQ in which a Spearman’s
rho of 0.49 was reported.1 So far no explanation exists for
the low correlation of these instruments with lung function.
The total score of the CCQ and its symptom domain, and
the total score and mastery domain of the CRQ-SR indicated
statistically significant and clinically meaningful differences
in themedium term. However, the responsiveness indicators
of the CRQ-SR diminished at 52 weeks unlike the CCQ, which
remained stable. Particularly, the mastery domain made
a noticeable decline from a statistically and a clinically
meaning meaningful difference of 1.14 to a non significant
difference of 0.04 units. Themental state domain of the CCQ
was not responsive probably because of ceiling effect (37%).
The attenuation of the responsiveness we detected for the
CRQ-SR has been reported for the interviewer-led version
previously.6 This could not be explained by regression to the
mean as the CCQ detected statistically and clinically signif-
icant changes at both 26 and 52 weeks in line with our
expectation. Therefore, as the CRQ is unstable, its long-term
responsiveness in clinical trials involving smokers with mild
to moderate COPD is questionable.
We used a p-value of 0.001 to guard against false posi-
tive findings as other investigators did.7 We chose this figured. baseline measurements.a
Functional state Mental state FEV1
0.53* 0.57* 0.05
0.43* 0.65* 0.06
0.50* 0.46* 0.16
0.43* 0.20* 0.06
0.62* 0.64* 0.08
0.18 0.12 1.00
Table 5 Mean change in baseline scoresa among participants with prolonged abstinence from smoking at 26 weeks and 52
weeks after the target quit date.
Questionnaire 26 weeks 52 weeks
CRQ-SR domains Mean difference (SD) N Mean difference (SD) N
Fatigue 0.27 (1.23) 69 0.18 (0.81) 30
Emotional function 0.36 (1.07) 69 0.40 (0.67) 30
Mastery D1.14 (0.82)* 68 0.04 (0.93) 30
Dyspnoea D0.73 (1.20) 25 D0.60 (1.18) 16
Total D0.67(0.92)* 69 0.38(0.57) 30
CCQ domains
Total D0.54 (0.50)* 62 D0.43(0.44)* 28
Symptom D1.02 (0.81)* 67 D1.04 (0.97)* 30
Functional state 0.36 (0.54) 65 0.19 (0.52) 28
Mental state 0.25 (1.06) 63 0.11 (0.57) 28
*p < 0.001.
Wilcoxon Signed ranks test or related samples t-test were used to assess statistical significance. D change in unstandardized scores
greater than MCIDs, 0.4 unit for the CCQ and 0.5 unit for the CRQ. The CCQ is rated from 0 ‘best health state’ to 6 ‘worst health state’
and CRQ-SR from 1 ‘worst health state’ to 7 ‘best health state’.
a Positve differences were coded to indicate improvement, negative worsening.
1680 A.A. Reda et al.as corrections such as Bonferonni could have provided an
extremely conservative p-value due to the large number of
tests conducted. As we also used MCID as a significance
indicator, the actual significance level is higher than 0.001.
One of the limitations of our study is that it is based on
participants in the setting of an intervention trial. Our
participants were all current heavy smokers at study entry
who were motivated to quit smoking under the controlled
conditions of a trial. Hence, our findings are notFigure 1 The standardized mean difference (SMD) in scores
between baseling and 26 weeks follow-up provides an insight
into the difference in score changes between baseline and six
months among continous abstainers while overcoming the
difference in scale of the questionnaires. (SMD Z mean
difference divided by the within group SD. Positive differences
were scaled to indicate improvement, negative otherwise for
both instruments. D change in unstandardized scores greater
than respective MCIDs e 0.4 for the CCQ, 0.5 for the CRQ. The
CCQ was rated from 0 ‘best health state’ to 6 ‘worst health
state’ and CRQ-SR from 1 ‘worst health state’ to 7 ‘best health
state’. *p < 0.001).representative of the whole population of mild to moderate
COPD patients that are seen under routine primary care
conditions. Furthermore, aswe used data froma clinical trial
and because the scales were administered by more than the
recommended time of two weeks for conducting test-retest
reliability, we were not able to calculate intra-class corre-
lation coefficients. As a result, reliability analysis did not
proceed beyond internal consistency. Even though we had
good response rates at baseline as the participants were
motivated to participate, respondents failed to complete allFigure 2 The standardized mean difference (SMD) in scores
between baseline and 52 weeks follow-up provides an insight
into the difference in score changes between baseline and six
months among continous abstainers while overcoming the
difference in scale of the questionnaires. (SMD Z mean
difference divided by the within group SD. Positive differences
were scaled to indicate improvement, negative otherwise for
both instruments. D change in unstandardized scores greater
than respective MCIDs e 0.4 unit for the CCQ, 0.5 unit for the
CRQ. The CCQ was rated from 0 ‘best health state’ to 6 ‘worst
health state’ and CRQ-SR from 1 ‘worst health state’ to 7 ‘best
health state’. *p < 0.001).
Clinical COPD and chronic respiratory questionnaires 1681items as the questionnaires were self-administered. Even
though item-completion rate was not statistically associated
with important baseline characteristics we may not rule out
the possibility of bias. This fact, and partly, the low number
of quitters, has reduced the effective sample size available
for analysis. As a result we were not able to conduct validity
and reliability tests by stratifying the sample by sex, age etc.
The absence of evidence based guidelines on item-level
missing value replacement is also a limitation. However, to
examine the influence of missing values we conducted
sensitivity analyses using 100% item-completion rates. The
analyses showed limited variation of the key reliability and
validity indicators.
This study is the first to examine and compare the CCQ
and CRQ-SR questionnaires. Our report has one of the
longest follow-up periods compared to previous studies. It
is also the first to examine the longer term responsiveness
of the CCQ. We have also effectively used current knowl-
edge on the importance of smoking cessation in improving
patients’ HRQoL10,20,21 unlike previous studies that
employed specific medical symptoms and signs to examine
COPD progression.
We conclude that the CCQ is a valid, reliable and
responsive instrument in cases with mild to moderate COPD
for both medium and longer term follow-up. The CRQ-SR
has good indicators for the medium term but its respon-
siveness declines in the longer term. There is poor
discriminative validity for both questionnaires. Both ques-
tionnaires have good convergent validity with each other,
but not with FEV1 post-bd. measurements. Thus, the two
questionnaires are suitable for prospective monitoring of
self-reported respiratory health status but are not suitable
for diagnostic purposes. Future longitudinal studies
involving mild to moderate cases of COPD could use both
the CCQ and CRQ-SR if their time frame is limited to
medium term time frames such as 6 months. However,
when the follow-up exceeds 6 months, the CCQ is the
recommended alternative. This is also considering the
favourable feasibility of the CCQ.
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